The impact of chronic rhinosinusitis on COVID-19 risk and outcomes: A systematic review and meta-analysis.
COVID-19
chronic rhinosinusitis
coronavirus
epidemiology
prevalence
steroids
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
01
2023
accepted:
20
03
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
The impact of chronic rhinosinusitis (CRS) and subsequent steroid therapy on acquiring COVID-19 and severe outcomes remains controversial. Therefore, we conducted this systematic review and meta-analysis to provide cumulative evidence regarding the risk of COVID-19 and the impact of steroid therapy, length of hospital stay, mechanical ventilation, and mortality among CRC patients. We conducted a comprehensive electronic search strategy using the relevant keywords. The outcomes and risk factors of COVID-19 in CRS patients was estimated and compared to a healthy control group when applicable. A total of seven studies were included, with an estimated prevalence of 6.5% (95% confidence interval (CI): 2.5-15.7) for COVID-19 in the CRS group. COVID-19 prevalence did not differ between CRS and controls (odds ratio (OR): 0.92; 95%CI: 0.84-1.01; p = 0.08). Moreover, using steroid/immunosuppressive therapy did not significantly increase the risk of acquiring COVID-19 in CRS patients compared to the control group (OR: 3.31; 95%CI: 0.72-15.26; p = 0.12). Length of hospital stay, mechanical ventilation, and mortality rates were comparable between the two groups. Furthermore, we found that male sex, cardiovascular morbidity, renal diseases, and hypertension were inversely associated with COVID-19 infection (p < 0.01). CRS had a neutral effect on acquiring COVID-19 and developing severe outcomes. However, further studies are needed.
Sections du résumé
Background
The impact of chronic rhinosinusitis (CRS) and subsequent steroid therapy on acquiring COVID-19 and severe outcomes remains controversial. Therefore, we conducted this systematic review and meta-analysis to provide cumulative evidence regarding the risk of COVID-19 and the impact of steroid therapy, length of hospital stay, mechanical ventilation, and mortality among CRC patients.
Methods
We conducted a comprehensive electronic search strategy using the relevant keywords. The outcomes and risk factors of COVID-19 in CRS patients was estimated and compared to a healthy control group when applicable.
Results
A total of seven studies were included, with an estimated prevalence of 6.5% (95% confidence interval (CI): 2.5-15.7) for COVID-19 in the CRS group. COVID-19 prevalence did not differ between CRS and controls (odds ratio (OR): 0.92; 95%CI: 0.84-1.01; p = 0.08). Moreover, using steroid/immunosuppressive therapy did not significantly increase the risk of acquiring COVID-19 in CRS patients compared to the control group (OR: 3.31; 95%CI: 0.72-15.26; p = 0.12). Length of hospital stay, mechanical ventilation, and mortality rates were comparable between the two groups. Furthermore, we found that male sex, cardiovascular morbidity, renal diseases, and hypertension were inversely associated with COVID-19 infection (p < 0.01).
Conclusion
CRS had a neutral effect on acquiring COVID-19 and developing severe outcomes. However, further studies are needed.
Identifiants
pubmed: 37063875
doi: 10.3389/fimmu.2023.1139031
pmc: PMC10090854
doi:
Substances chimiques
Steroids
0
Types de publication
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1139031Informations de copyright
Copyright © 2023 Reda, Lashin, Alaaraj, Abouelkheir, Ahmed, Shah and El-Qushayri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Allergy Clin Immunol Pract. 2020 May;8(5):1505-1511
pubmed: 32389275
Laryngoscope. 2022 Feb;132(2):257-258
pubmed: 34806184
Allergy. 2021 Mar;76(3):789-803
pubmed: 33210729
Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):8-15
pubmed: 33164997
J Allergy Clin Immunol. 2020 Jul;146(1):218-220.e2
pubmed: 32417136
Otolaryngol Head Neck Surg. 2022 Jan;166(1):183-185
pubmed: 33845681
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
PLoS One. 2021 Mar 4;16(3):e0247461
pubmed: 33661992
J Allergy Clin Immunol. 2020 Jul;146(1):203-206.e3
pubmed: 32333915
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Otolaryngol Head Neck Surg. 2009 Oct;141(4):454-61
pubmed: 19786212
Clin Infect Dis. 2021 Jun 1;72(11):e695-e703
pubmed: 32945846
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2492-2494
pubmed: 32592789
J Allergy Clin Immunol Pract. 2020 Nov - Dec;8(10):3597-3599.e2
pubmed: 32980581
Infez Med. 2020 Dec 1;28(4):469-474
pubmed: 33257620
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e303-e304
pubmed: 32330323
Eur Respir J. 2022 Mar 31;59(3):
pubmed: 34385278
J Allergy Clin Immunol. 2020 Oct;146(4):790-798
pubmed: 32810517
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e433-e434
pubmed: 32339362
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1105-1111
pubmed: 28132798
J Allergy Clin Immunol Pract. 2022 Jun;10(6):1423-1432
pubmed: 35307579
J Chin Med Assoc. 2020 Mar;83(3):217-220
pubmed: 32134861
GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc07
pubmed: 22073111
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1152-1162.e3
pubmed: 33495097
Otolaryngol Head Neck Surg. 2010 Jan;142(1):64-71
pubmed: 20096225
J Allergy Clin Immunol. 2008 Nov;122(5):961-8
pubmed: 18804271
Laryngoscope. 2013 Oct;123(10):2347-59
pubmed: 23553558
Curr Opin Otolaryngol Head Neck Surg. 2004 Jun;12(3):237-42
pubmed: 15167036
Ear Nose Throat J. 2021 Aug 20;:1455613211038070
pubmed: 34414811
Laryngoscope. 2004 Nov;114(11):1895-905
pubmed: 15510011
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
J Allergy Clin Immunol. 2011 Oct;128(4):693-707; quiz 708-9
pubmed: 21890184
Physiol Rev. 2018 Apr 1;98(2):781-811
pubmed: 29488821
Laryngoscope. 2013 May;123(5):1070-4
pubmed: 23553255
Med Sci (Basel). 2019 Mar 27;7(4):
pubmed: 30934800
Allergy. 2020 Oct;75(10):2440-2444
pubmed: 32233040
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2645-2655.e14
pubmed: 33684635
J Asthma. 2022 May;59(5):866-879
pubmed: 33556287
Allergy. 2021 Mar;76(3):677-688
pubmed: 33075144
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2262-2271.e2
pubmed: 33931377
Am J Otolaryngol. 2022 Jul-Aug;43(4):103469
pubmed: 35576660